ICMJE DISCLOSURE FORM

Date: 2/4/2025

Your Name: Marc Bonten

Manuscript Title: Biomarker geleide antibiotisch stewardship bij “community-acquired” pneumonie

Manuscript Number (if known): D8412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		Merck	Payments to UMCU
		GSK	Payments to UMCU
		HORIZON funding (ECRAID-Base, ECRAID-PRIME, COMECT)	
		IHI funding (COMBACTE-Net, COMBACTE-Care, CIMBACTE-Magnet, COMBACTE-CDI, VITAL, Primavera)	
		Sequiris	Payments to Ecraid
		TechnoPhage	Payments to Ecraid
		Attea Pharma	Payments to Ecraid
		Phaxiam	Payments to Ecraid
		Janssen Vaccines	Payments to Ecraid

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☒ **None**	
4	Consulting fees	☐ **None**	
		Advisory Boards Merck, GSK, Janssen Vaccines	All payments to UMCU
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ **None**	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☒ **None**	
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ **None**	
		Sanofi	Payments to UMCU
10	Leadership or fiduciary role in other board,	☐ **None**	
		CEO of Ecraid	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.